(E)-1-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)-3-(4-chlorophenyl)prop-2-en-1-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-1-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)-3-(4-chlorophenyl)prop-2-en-1-one
• 英文别名: (E)-3-(4-chlorophenyl)-1-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)prop-2-en-1-one
• 化学式: C₁₆H₁₄ClNOS
• 分子量: 303.812
• InChiKey: ANMBOUFLFLPTES-ZZXKWVIFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  48.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  对氯肉桂酸 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 7.5h， 生成 (E)-1-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)-3-(4-chlorophenyl)prop-2-en-1-one
  参考文献：
  名称：

  Design, Synthesis and Pharmacological Evaluation of Novel Piperlongumine derivatives as Potential Antiplatelet Aggregation Candidate

  摘要：

  A series of novel piperlongumine derivatives (4a‐i, 6a‐i) were designed and synthesized. The inhibitory activities of platelet aggregation induced by ADP and AA in vitro have been evaluated by bron turbidimetry and liver microsomal incubated assay. The assay results show that compounds 4e and 6e exhibited remarkable potency to that of the positive control piplartine and aspirin.

  DOI：

  10.1111/cbdd.12714

文献信息

• 荜茇酰胺类似物、制备方法及其应用
  申请人：安徽中医药大学

  公开号：CN104910174B

  公开（公告）日：2017-03-22

  本发明涉及药物化学领域，具体涉及一类荜茇酰胺类似物(I)或(II)、制备方法以及含有它们的药物组合物，药效学试验证明，本发明的荜茇酰胺类似物可用于治疗或预防血栓栓塞性疾病。
• Design, Synthesis and Pharmacological Evaluation of Novel Piperlongumine derivatives as Potential Antiplatelet Aggregation Candidate
  作者：Yujun Wang、Jie Wang、Jiaming Li、Yanchun Zhang、Weijun Huang、Jian Zuo、Huicai Liu、Di Xie、Panhu Zhu

  DOI：10.1111/cbdd.12714

  日期：2016.6

  A series of novel piperlongumine derivatives (4a‐i, 6a‐i) were designed and synthesized. The inhibitory activities of platelet aggregation induced by ADP and AA in vitro have been evaluated by bron turbidimetry and liver microsomal incubated assay. The assay results show that compounds 4e and 6e exhibited remarkable potency to that of the positive control piplartine and aspirin.